Weight-loss drugs like Ozempic and Wegovy are continuing to spook financial advisers when it comes to investing money in junk and fast food companies.
Some experts predict these companies – already battling a rise in health conscious customers – could face a tobacco-like demise due to the increasingly popular drugs, which reduce cravings and make people feel full longer.
The doughnut company Krispy Kreme is the latest to feel the effects of the weight-loss movement and saw its share price drop Monday.
Read more here
Published by Alexa Lardieri
I am a reporter and digital producer for the Civic section of U.S. News & World Report, where I write about breaking news. I came to U.S. News in 2016 as a researcher and writer for the Rankings and Reviews section and in 2017, joined the news team, where I helped launch America 2020. I have previously worked for LifeZette.com as a reporter and social media specialist and was an editor for several outlets at my alma mater. I am a graduate of the Philip Merrill College of Journalism at the University of Maryland, College Park. You can follow me on Twitter (@arlardieri) and Facebook (/AlexaRLardieri) or connect with me on LinkedIn (/in/alexa-lardieri).
View more posts
Alexa Lardieri 